{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-037951","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.120535+00:00","generated_at":"2026-06-15T06:37:16.077173+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Bluejay Diagnostics Q1 net loss $2.5M, cash $6.8M; focuses on FDA pathway","bullets":["Net loss of $2.5M ($0.12/shr) vs $2.0M ($0.10/shr) in Q1 2022.","Cash and equivalents fell to $6.8M at March 31, 2023 from $10.1M at Dec 31, 2022.","R&D expense rose to $1.4M from $695k, driven by clinical trial and personnel costs.","CEO notes resources aligned with FDA feedback to optimize Symphony IL-6 approval pathway.","No revenue reported; pre-commercial stage diagnostics company."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-037951","json":"https://secwatch.observer/filing/0001213900-23-037951.json","markdown":"https://secwatch.observer/filing/0001213900-23-037951.md","text":"https://secwatch.observer/filing/0001213900-23-037951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023037951/0001213900-23-037951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023037951/ea178223-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:37:16.077173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"adccd2cfa93727bb930b09da4e18c212f3e1214e","claim":"Bluejay Diagnostics, Inc. reported quarter ended March 31, 2023 results: net income $2.5 million, or $0.12 per share, EPS $0.12 per share.","evidence_excerpt":"The net loss was $2.5 million, or $0.12 per share for the three months ended March 31, 2023, compared to $2.0 million, or $0.10 per share, for the comparable period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390023037951/0001213900-23-037951-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Net income","value":"$2.5 million, or $0.12 per share"},{"label":"EPS","value":"$0.12 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}